Giant leap for MannKind's Affrezza as Colby takes immunotherapies off back burner
This article was originally published in Scrip
Executive Summary
MannKind stands to gain up to $140 million in upfront and milestone payments plus royalties under a license agreement with Colby Pharmaceutical, which will take over development of novel MKC1106 immunotherapies, allowing MannKind to move another oncology asset forward while remaining focused on Phase III development of its inhaled diabetes drug Affrezza.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.